· By Sanofi Admin

Drug Development 101: PDUFA

PDUFA

This post was authored by Barry Sickels, Vice President, Regulatory Affairs at Sanofi US
Earlier this month, we shared an overview of Advisory Committee Meetings, as part of our new Drug Development 101 series. Today, we’re sharing the mechanics of another important element of the drug development and approval process, the Prescription Drug User Fee Act […]

VIEW FULL POST
 · By Brandi Robinson

Sanofi Q2 2015 Earnings Results Infographic

For full financial data and non-GAAP reconciliations, please refer to Sanofi’s Q2 Update Results and Presentation issued July 30, 2015 available at http://en.sanofi.com/investors/investors.aspx.
More information is also available via the press release:  http://www.multivu.com/players/English/7569551-sanofi-results-q2-2015/

 

VIEW FULL POST
 · By Sanofi Admin

Drug Development 101: Advisory Committee Meetings

Source: FDA.gov

This post was authored by Barry Sickels, Vice President, Regulatory Affairs at Sanofi US
Do you know what happens after a promising new compound is discovered in a lab? The journey from compound to patient is a long one – in fact, it takes an average of about 10-15 years. It’s also a process that many […]

VIEW FULL POST
 · By voicesonpolicy

A Discussion with Our Local Member of Congress – Leonard Lance

Rep Leonard Lance headshot

Today at Sanofi US, we hosted Congressman Leonard Lance as part of the ExL Pharma Public Relations & Communications Summit. Lance serves New Jersey’s 7th Congressional District, since being elected to the House of Representatives in 2008. Lance is a member of The House Energy and Commerce Committee, which just passed landmark legislation with the […]

VIEW FULL POST